A trial to study the effects of atomoxetine and osmotic release oral system-methylphenidate on executive functions in patients with combined type attention-deficit/hyperactivity disorder

Trial Profile

A trial to study the effects of atomoxetine and osmotic release oral system-methylphenidate on executive functions in patients with combined type attention-deficit/hyperactivity disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top